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 MI remains a major cause of morbidity
and mortality despite major treatment
advances achieved during the past
decades.
 Administration of an engineered
myocardial graft, composed of
decellularized myocardial matrix reﬁlled
with ATDPCs (EMG-ATDPC), in a porcine
pre-clinical MI model, may support
cardiac recovery following MI.
 Thirty days post-EMG-ATDPC implanta-
tion, cardiac magnetic resonance imaging
and comprehensive histological analysis
were performed to evaluate its impact on
myocardial restoration.
 EMG-ATDPC resulted in better left
ventricular ejection fraction, higher
vessel density and neovascularization,
and reduced infarct size by 68%, as well
as limited ﬁbrosis.
 Accordingly, EMG-ATDPC is ready to start
the translational avenue toward phase I
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AB BAND ACRONYM S
ATDPC = adipose tissue-
derived progenitor cells
CMR = cardiac magnetic
resonance imaging
cTnI = cardiac troponin I
EMG = engineered myocardial
graft
GFP = green ﬂuorescent
protein
IsoB4 = isolectin B4
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MaMyocardial infarction (MI) remains a dreadful disease around the world, causing irreversible sequelae that
shorten life expectancy and reduce quality of life despite current treatment. Here, the authors engineered a
cell-enriched myocardial graft, composed of a decellularized myocardial matrix reﬁlled with adipose tissue-
derived progenitor cells (EMG-ATDPC). Once applied over the infarcted area in the swine MI model, the EMG-
ATDPC improved cardiac function, reduced infarct size, attenuated ﬁbrosis progression, and promoted neo-
vascularization of the ischemic myocardium. The beneﬁcial effects exerted by the EMG-ATDPC and the absence
of identiﬁed adverse side effects should facilitate its clinical translation as a novel MI therapy in humans.
(J Am Coll Cardiol Basic Trans Science 2016;1:360–72) © 2016 The Authors. Published by Elsevier on behalf of
the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
left ventricle/ventricular
= left ventricularLV =
LVEFejection fraction
MI = myocardial infarction
pATDPC = porcine adipose
tissue-derived progenitor cell
SMA = smooth muscle actinC ardiovascular disease is the foremost causeof death worldwide, accounting for almost30% of all deaths and exceeding other
growing pandemics, such as diabetes mellitus, can-
cer, and respiratory infections (1). Myocardial infarc-
tion (MI) leads to massive cardiomyocyte loss,
collagen scar formation, and ultimately, maladaptive
adverse ventricular remodeling (2). Cardiac homeo-
stasis self-regeneration is insufﬁcient following MI
injury (3,4). Hence, alternative therapies—including
cell and gene therapy and tissue engineering—are be-
ing investigated as a means of overcoming current
therapeutic limitations and challenges.SEE PAGE 373Cardiac tissue engineering uses natural or synthetic
support platforms generating functional grafts that
can be tightly implanted over injured myocardium
(5,6). For optimal cell seeding, the supporting material
or scaffold should provide a biomimetic niche resem-
bling the physiological microenvironment, supplying
the necessary cues to direct cell differentiation
and proliferation, and favoring electromechanical
coupling with host tissue (7,8). Decellularized myo-
cardial extracellular matrix meets these requirements
because it preserves the native myocardium ultra-
structure, mechanical properties, and local matrix
milieu (9–12). A recent study reports a reﬁned protocol
for obtaining an optimal myocardial scaffold forMinisterio de Ciencia e Innovación [SAF2014-59892-R]; Red de Terapia Ce
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qualities of decellularized myocardial scaf-
folds, few studies have investigated their use
in pre-clinical MI animal models. To date, only
1 report describes administration of a decel-
lularized myocardial scaffold in swine, and it was a
cell-free scaffold (13).
In our present study, we applied in a swine acute
MI model a novel engineered myocardial graft (EMG)
obtained by decellularization of porcine myocardial
tissue. Decellularized myocardial scaffolds were left
acellular (EMG-cell free) or were repopulated with
green ﬂuorescent protein (GFP)-labeled porcine adi-
pose tissue-derived progenitor cells (GFPþ pATDPCs)
to generate cell-enriched grafts (EMG-ATDPC). Both
engineered grafts (EMG-cell free and EMG-ATDPC)
were applied over infarcted myocardium in alloge-
neic wild-type swine to assess cardiac function and
modulation of scar healing.
METHODS
GENERATION OF EMGs. Myocardial decellularization
was performed as previously described (Figure 1) (9).
Brieﬂy, porcine myocardial tissue slices ofw25  25 
3 mm were initially treated for 72 h with 1% sodium
dodecyl sulfate (Sigma-Aldrich, St. Louis, Missouri),
followed by a 48-h treatment with Triton X-100
(Sigma-Aldrich). Both solutions were replaced everylular-TerCel (RD12/0019/0029), Red de Investigación
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FIGURE 1 Development of EMG-ATDPC and Experimental Design of the in Vivo Study
Main steps involved in EMG-ATDPC obtaining from porcine myocardial tissue are shown. n indicates number of pigs. CMR ¼ cardiac magnetic
resonance imaging; EMG-ATDPC ¼ engineered myocardial graft repopulated with porcine adipose tissue-derived progenitor cells (pATDPC);
MI ¼ myocardial infarction. Scale bars ¼ 1 cm.
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washed with phosphate-buffered saline containing
1% penicillin/streptomycin (Gibco, Grand Island, New
York), 3 times for 24 h each. All of these steps were
repeated twice, and the tissue was washed with
sterile distilled water between cycles. Following
completion of the second cycle, a 72-h DNase I
(Roche, Basel, Switzerland) digestion was performed.
The obtained decellularized myocardial scaffolds
were next lyophilized in a freeze-drier chamber
(Christ loc-1 m, B. Braun Biotech International,
Melsungen, Germany), sterilized with a certiﬁed
gamma irradiation dosage of 30 kGy (Aragogamma,
Barcelona, Spain), and stored at room temperature
until use.
The EMG-ATDPC was generated by rehydrating the
decellularized myocardial scaffold using a mixture of
175 ml of peptide hydrogel RAD16-I (Corning, Corning,
New York) and 175 ml of 1.75  106 GFPþ pATDPCs in
10% sucrose (Sigma-Aldrich) (Figure 2A). pATDPCs
used were isolated and cultured from pericardial ad-
ipose tissue as previously described (14). To obtainthe EMG-cell free, the decellularized myocardial
scaffold was only rehydrated with 350 ml of RAD16-I
hydrogel. Fifteen minutes later, 350 ml of a-MEM
(Sigma-Aldrich) was added to the EMG (Figure 2B),
and constructs (EMG-ATDPC or EMG-cell free) were
implanted in the infarcted area.
EXPERIMENTAL DESIGN. All study procedures
followed the guidelines regarding the use of animals
in research as established in the Guide for the Care
and Use of Laboratory Animals (NIH Publication No.
80-23, revised 1996), and conformed to the principles
outlined in the Declaration of Helsinki. The study was
approved by the local Animal Experimentation Unit
Ethical Committee (Number: ES 100370001499).
A total of 16 crossbred Landrace  Large White pigs
(39.0  3.7 kg) were randomly distributed in the
following 3 groups:
1. EMG-cell free (n ¼ 8), with MI induction and
EMG-cell free implantation;
2. EMG-ATDPC (n ¼ 10), with MI induction and
EMG-ATDPC treatment; and
FIGURE 2 EMG-ATDPC Preparation and Implantation, and Post-MI Morphometric Analysis
(A) The myocardial scaffold was embedded with the mixture of hydrogel and GFPþ pATDPCs. (B) Then culture medium was added, to facilitate
hydrogel geliﬁcation and to generate the deﬁnitive EMG-ATDPC. Scale bars ¼ 1 cm. (C) EMG-ATDPC (surrounded by a dotted yellow line)
engrafted in the porcine heart over the MI performed by a coronary artery ligation (indicated with a yellow asterisk). (D) Panoramic micro-
photograph of the implanted EMG-ATDPC over the myocardium, with histological assessment under Masson’s trichrome and (E) Movat’s
pentrachrome stains. Scale bars ¼ 100 mm. (F) Representative images showing the intact EMG (black arrowheads) retained over the infarcted
myocardium (discontinuous black line) after animal sacriﬁce in EMG-cell free and (G) EMG-ATDPC pigs. (F0)Magniﬁcation of the infarcted area
and EMG in the EMG-cell free and (G0) EMG-ATDPC groups, respectively. (H) Percentage of LV infarct area measured in the EMG-ATDPC and
EMG-cell free groups. Data are expressed as mean  SEM. *p ¼ 0.048. GFP ¼ green ﬂuorescent protein; LV ¼ left ventricle; Myo ¼ host
myocardium; RV ¼ right ventricle; other abbreviations as in Figure 1.
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3643. EMG-sham (n ¼ 2), with no MI and EMG-ATDPC
over healthy myocardium.
Acute MI was induced by performing a left lateral
thoracotomy, followed by permanent double ligation
of the ﬁrst marginal branch of the circumﬂex artery,
as previously described (15). Thirty minutes later, the
EMG-ATDPC or EMG-cell free was attached over the
infarcted area using surgical glue (Glubran2, Car-
diolink, Barcelona, Spain) (Figure 2C). To ensure in-
duction of similar MI, blood samples were collected
from all animals through jugular venipuncture at
baseline and 2 h post-MI. The circulating cardiac
biomarkers cardiac troponin I (cTnI) and creatinine
kinase were measured using a ﬂuorometric immuno-
assay analyzer (AQT90 FLEX, Radiometer Medical,
Brønshøj, Denmark). Following completion of these
procedures, the animals were housed for 1 month
before sacriﬁce.
CARDIAC FUNCTION EVALUATION. Investigators
blinded to treatment groups assessed the animals’
cardiac function using cardiac magnetic resonance
imaging (CMR) at 1.5-T (Intera, Philips, Amsterdam,
the Netherlands) with a 4-channel, phased array
surface coil (SENSE Body Coil). Acquired images were
taken in apnea with electrocardiogram gating. At 3
time points—baseline, 48 h post-MI, and 1 month after
treatment—we analyzed the following cardiac
parameters: cardiac output, end-diastolic wall mass,
left ventricular end-diastolic volume, left ventricular
ejection fraction (LVEF), left ventricular end-systolic
volume, and stroke volume.
HISTOPATHOLOGICAL EXAMINATION. Animals were
sacriﬁced by administering an anesthesia overdose at
33.4  4.2 days after the initial MI induction. Porcine
hearts were then excised and sectioned. Extracted
biopsies were embedded in Tissue O.C.T. compound
(VWR Chemicals, Radnor, Pennsylvania), snap-frozen
in liquid nitrogen, and then properly stored until
analysis.
For morphometric quantitation of infarct size, the
left ventricular (LV) infarct area was measured in
photographed heart sections, 1.5 cm distally to
the coronary ligation. Quantiﬁcation was performed
using Image J software (version 1.48, National
Institutes of Health, Bethesda, Maryland). Infarct size
was double-blindly measured by 2 independent
investigators and calculated as the percentage of the
LV infarct area relative to the LV total area.
Histological analyses of 10-mm frozen sections were
performed with hematoxylin/eosin, Masson’s tri-
chrome, and Movat’s pentachrome stains. We also
used picrosirius red staining for scar ﬁbrosis analysis
to examine collagen deposition and changes in theamounts of type I and III collagens. Total collagen and
speciﬁc I and III types were quantiﬁed for 6 random
ﬁelds using Image-Pro Plus software (version 6.2.1,
Media Cybernetics, Rockville, Maryland).
For detailed information about immunohisto-
logical analysis, see the Supplemental Appendix.
STATISTICAL ANALYSIS. Statistical analyses were
performed using the statistics program SPSS (version
20, IBM, Armonk, New York). Both cardiac function
differences and quantitative histopathological eval-
uation between groups were compared using the
Student t test for paired and independent samples.
Baseline CMR parameters differences were assessed
with an analysis of variance test. Data are represented
as mean  SEM, and a p value <0.05 was considered
statistically signiﬁcant.
RESULTS
Following MI induction, 1 animal died due to ven-
tricular ﬁbrillation, 1 exhibited no evidence of MI and
was thus not considered in the ﬁnal analysis, and
2 animals were excluded due to post-surgical infec-
tion associated with inappropriate EMG handling
during the preparation process before implantation.
Thus, a total of 16 animals were ﬁnally included in the
analysis (cardiac function and histopathology),
distributed as follows: 7 in the EMG-cell free group, 7
in the EMG-ATDPC, and 2 in the EMG-sham group
(Figure 1). The EMG-cell free and EMG-ATDPC groups
showed similar levels of the circulating cardiac
markers cTnI (0.06  0.02 mg/l vs. 0.03  0.05 mg/l;
p ¼ 0.55) and creatinine kinase MB (0.66  0.29 mg/l
vs. 0.43  0.19 mg/l; p ¼ 0.52), indicating similar MI
induction in both groups. After macroscopic and
microscopic examination, in 10 animals of 16 (n ¼ 6
and n ¼ 4 for EMG-cell free and EMG-ATDPC groups,
respectively), the EMG remained properly attached to
the underlying myocardium and was identiﬁable at
both levels after 1 month (Figures 2D to 2G0). In the
remaining animals, the EMG was reabsorbed and
could not be distinguished following sacriﬁce.
EMG-ATDPC IMPLANTATION REDUCED INFARCT SIZE
AND IMPROVED CARDIAC FUNCTION. LV infarct size
was 68% smaller in the EMG-ATDPC compared with
the EMG-cell free group (2.5  0.6% vs. 7.6  2.3%,
respectively; p ¼ 0.048) (Figure 2H).
Baseline CMR data analysis showed no differences
between the studied groups (Supplemental Table 1).
Cardiac function assessed by LVEF at 1 month
follow-up after infarction signiﬁcantly improved in
the EMG-ATDPC group (50.8  2.6% vs. 61.3  3.4%;
p ¼ 0.001) and remained nonsigniﬁcant in the
EMG-cell free group (48.4  3.0% vs. 52.9  2.2%;
FIGURE 3 Cardiac Function Evaluation by CMR
(A)T1 short-axis delayedenhancement images fromEMG-cell free andEMG-ATDPCanimals, at48hafterMI induction (upperpanels)andat 1month,
before sacriﬁce (lower panels). (B) LVEF dynamics between baseline and 1 month for EMG-cell free and EMG-ATDPC groups, respectively. Data are
shownasmean SEM. *p¼0.047. (C) LVEF for EMG-cell free and EMG-ATDPCgroups at indicated timepoints: baseline, 48h post-MI, and 1month.
Values are expressed asmean SEM. *p¼ 0.041, †p¼ 0.001. (D) SV differential values between baseline and 1 month for EMG-cell free and EMG-
ATDPCgroups. Data are represented asmean SEM. #p¼0.08 (trend). (E) LVESV differentialmeasures between 48 h post-MI and after 1month of
follow-up for EMG-cell free and EMG-ATDPC animals. Data indicated as mean SEM. ##p ¼ 0.09 (trend). CMR ¼ cardiac magnetic resonance;
LVEF ¼ left ventricular ejection fraction; LVESV ¼ left ventricular end-systolic volume; SV ¼ stroke volume; other abbreviations as in Figure 1.
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were observed for stroke volume (6.1  1.6 ml
vs. 1.5  4.0 ml, p ¼ 0.08, for EMG-ATDPC vs. EMG-
cell free, respectively) and LV end-systolic volume(8.1  1.4 ml vs. 1.0  3.5 ml, p ¼ 0.09, for
EMG-ATDPC vs. EMG-cell free, respectively), indi-
cating limited ventricular remodeling in treated
animals (Figures 3D and 3E).
TABLE 1 CMR-Derived Cardiac Function Parameters
EMG-Sham (n ¼ 2) EMG-Cell Free (n ¼ 7) EMG-ATDPC (n ¼ 7)
48 h Post-Intervention 1 Month p Value 48 h Post-MI 1 Month p Value 48 h Post-MI 1 Month p Value
CO (l/min) 2.9  0.5 3.1  0.5 0.76 3.1  0.4 2.9  0.1 0.41 2.9  0.1 2.9  0.2 0.95
EDWM (g) 66.9  9.7 68.2  5.6 0.81 69.9  5.5 68.4  4.7 0.60 69.0  3.2 71.1  3.5 0.42
LVEDV (ml) 61.5  6.3 60.5  10.0 0.83 64.7  5.5 67.0  5.1 0.63 66.2  2.7 62.9  2.6 0.21
LVEF (%) 54.4  5.0 60.2  0.3 0.44 48.4  3.0 52.9  2.2 0.30 50.8  2.6 61.3  3.1 0.001
LVESV (ml) 27.7  0.2 24.1  3.8 0.53 33.3  3.3 32.3  3.6 0.77 32.8  2.5 24.7  2.8 0.001
SV (ml) 33.8  6.6 36.4  6.2 0.08 31.4  3.3 34.7  1.9 0.34 33.5  1.7 38.2  1.1 0.03
Values are mean  SEM. Cardiac function parameters in the EMG-sham, EMG-cell free, and EMG-ATDPC groups are at 48 h after MI induction (or post-intervention for
EMG-sham) and at the time of sacriﬁce (1 month). The p values in bold are statistically signiﬁcant.
ATDPC ¼ adipose tissue-derived progenitor cells; CMR ¼ cardiac magnetic resonance; CO ¼ cardiac output; EDWM ¼ end-diastolic wall mass; EMG ¼ engineered myocardial
graft; LVEDV ¼ left ventricular end-diastolic volume; LVEF ¼ left ventricular ejection fraction; LVESV ¼ left ventricular end-systolic volume; MI ¼ myocardial infarction;
SV ¼ stroke volume.
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366EMG-ATDPC PROMOTED NEOVASCULARIZATION OF
SUBJACENT MYOCARDIUM AND INCREASED VESSEL
DENSITY. EMG-ATDPC displayed notable vasculari-
zation, including formation of new vessels inside the
construct (Figures 4A and 4B), with presence of
erythrocytes and polymorphonuclear cells within,
conﬁrming functional conduits with blood ﬂow
(Figure 4C). These vessels showed positive staining
for smooth muscle actin (SMA) in the tunica media
(Figure 4D) and for CD31 and isolectin B4 (IsoB4) in
the endothelial layer comprising the tunica intima
(Figures 4E and 4F). Interestingly, some of the newly
formed vessels connected the EMG-ATDPC with the
underlying myocardium (Figures 4G to 4I), conﬁrming
its integration with the vascular network of the
host myocardium. Moreover, vessel quantiﬁcation
revealed 2-fold higher vessel area in the EMG-ATDPC
animals than in the EMG-cell free animals, both in the
infarct core (3.6  0.5% vs. 1.7  0.1%; p ¼ 0.011) and
within the EMG (3.3  0.3% vs. 1.5  0.2%; p < 0.001)
(Figure 4J).
GFPD pATDPCs MIGRATED TO THE HOST MYOCARDIUM
AND EXPRESSED ENDOTHELIAL MARKERS. Histological
analysis of the EMG-ATDPC explanted hearts revealed
GFPþ pATDPCs within the EMG (Figure 5A), as well as
cell migration to the underlying infarct core
(Figure 5B). Implanted cells were positive for SMA,
maintaining its baseline expression, and remarkably,
de novo expressed CD31 and IsoB4 (Figures 5C to 5E,
Supplemental Figure 1). Altogether, this suggests that
the introduced cell lineage contributed to the gener-
ation of new vessels and increased vascularization.
These results also provided evidence of the commit-
ment of pATDPCs toward an endothelial differentia-
tion phenotype.
Evaluation of cell proliferative status in the infarct
core revealed that GFPþ pATDPCs exhibited nuclear
co-staining with phospho-histone H3, a marker ofactive proliferation (data not shown). The total
phospho-histone H3-positive cell count in the infarct
core was almost 2-fold higher in the EMG-ATDPC
group compared with the EMG-cell free group
(1.5  0.2% vs. 0.8  0.2%, respectively; p ¼ 0.019)
(Supplemental Figure 2).
TREATMENT WITH EMG-ATDPC ATTENUATED
MYOCARDIAL FIBROSIS FOLLOWING MI. We further
examined the collagen content in the myocardial scar
following MI induction to assess how the EMG
engraftment affected ﬁbrosis progression (Figures 6A
to 6D). Focusing on the infarct area, total collagen
content was signiﬁcantly reduced in the EMG-ATDPC
group compared to the EMG-cell free group (28.6  6.1%
vs. 49.9  4.1%, respectively; p ¼ 0.016). Collagen
ﬁbril subtype analysis revealed reduced type I
collagen (19.8  4.6% vs. 46.3  4.4%; p ¼ 0.002) and
increased type III collagen (8.8  2.0% vs. 3.6  1.1%;
p ¼ 0.042) in EMG-ATDPC–treated animals. Hence,
the ratio of type I to III was also signiﬁcantly lower
in EMG-ATDPC animals (2.3  0.7 vs. 13.0  6.9;
p ¼ 0.032) (Figure 6E).
DISCUSSION
The present study is the ﬁrst, to our knowledge, to
test an EMG comprising a decellularized myocardial
scaffold plus adipose-derived progenitors (EMG-
ATDPC) in a pre-clinical MI model. Herein, we
investigated the functional beneﬁts derived from
EMG-ATDPC engraftment in terms of cardiac func-
tion, neovascularization, and scar healing. EMG-
ATDPC treatment led to improved contractility
(assessed by surrogate LVEF), 2-fold higher vascular
density in the infarct area, 3-fold smaller infarct size,
and modulation of scar healing with attenuated
ventricular remodeling.
The pATDPC lineage chosen to repopulate the
scaffold has previously exhibited cardiomyogenic
FIGURE 4 Analysis of Post-MI Vascularization After EMG-ATDPC Engraftment
(A) Masson’s trichrome and (B) Movat’s pentachrome stains reveal presence of blood vessels in the EMG-ATDPC (yellow and black arrowheads, respectively). Scale
bars ¼ 100 and 50 mm, in that order. (C) Hematoxylin/eosin staining showing functional blood vessels in EMG-ATDPC with presence of polymorphonuclear cells (black
arrowheads) and erythrocytes (yellow arrowheads) in the lumen. Scale bar ¼ 20 mm. (D) Images of the EMG-ATDPC with immunohistochemistry revealing neovessels
positive for SMA, (E) CD31, and (F) IsoB4 (red for all cases). Type III collagen (Col-III) was stained in green, and nuclei were counterstained with DAPI (blue). Scale bars ¼
20 mm. (G) Neovessels connecting the engrafted EMG-ATDPC with the host myocardium (arrowheads) revealed with Masson’s trichrome, (H) Movat’s pentachrome, and
(I) immunohistochemical staining (red indicates IsoB4; grey, cTnI; blue, nuclei). Scale bars ¼ 50 mm (G and H) and 20 mm (I). All images shown belong to the EMG-ATDPC
animal group. (J) Percentage of vascular density in the infarct core and inside the EMG in the EMG-cell free and EMG-ATDPC groups. Final data are shown as mean 
SEM. *p ¼ 0.011, †p < 0.001. cTnI ¼ cardiac troponin I; IsoB4 ¼ isolectin B4; SMA ¼ smooth muscle actin; other abbreviations as in Figures 1 and 2.
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FIGURE 5 Assessment of GFPþ pATDPC Migration and Endothelial Differentiation in EMG-ATDPC Animals
(A) Presence of GFPþ pATDPCs (green, white arrowheads) in the EMG and (B) within the infarct core. Cardiomyocytes were labeled with cTnI
(grey), myocardial matrix ﬁbers with type I collagen (Col-I, red), and nuclei were counterstained with DAPI (blue). (C) Photographs of the
infarct core of the EMG-ATDPC group with immunostaining for the endothelial markers SMA, (D) IsoB4, and (E) CD31 (red for all cases). Nuclei
were counterstained with DAPI (blue) and white arrowheads indicate the GFPþ pATDPCs (green) expressing the protein of interest. Scale
bars ¼ 20 mm. IC ¼ infarct core; other abbreviations as in Figures 1, 2 and 4.
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368commitment and regenerative potential appropriate
for cardiac tissue engineering (9,14,16). Moreover,
their inherent immunomodulatory capacity facilitates
delivery, eliminating the need for immunosuppres-
sive treatments in the context of allogeneic trans-
plantation (17,18). In vivo studies have also
demonstrated that ATDPC delivery within scaffolds of
diverse origin promotes remarkable cardiac function
improvement in mice (19), rat (20,21), and porcine
(14,22) MI models, supporting their suitability for
in vivo application.
To better understand the beneﬁcial effects exerted
by the EMG-ATDPC, we must examine the synergistic
contributions from the decellularized myocardial
scaffold and the pATDPCs. The decellularized
myocardial scaffold must preserve the native
myocardial matrix integrity and organization, such
that it can provide adequate cues to drive celldifferentiation and to ensure cell attachment, sur-
vival, and migration (23,24). We must also acknowl-
edge the role of the decellularized scaffolds
themselves, in terms of neovascularization and cell
recruitment. Engraftment of an acellular pericardial
scaffold over porcine infarcted myocardium can
reportedly prompt scaffold neoinnervation and neo-
vascularization (25). Decellularized myocardial scaf-
folds apparently attract endogenous endothelial and
smooth muscle cells, increasing vascular sprouting
(26), and enabling scaffold–host tissue connections
with vascular networks and irrigation of injured tis-
sue. Thus, the decellularized myocardial scaffold
both provides cellular supportive function and par-
ticipates in direct vascularization of ischemic
myocardium. Likewise, its porcine origin is advanta-
geous for 2 main reasons: ﬁrst, decellularized scaf-
folds can be easily obtained from pig hearts, with high
FIGURE 6 Determination of Collagen Content and Composition in the Infarct Core
(A and B) Representative bright light microscopy images with sirius red staining distinguishing collagen ﬁbers (red) and healthy myocardium
(yellow/orange) from EMG-cell free and EMG-ATDPC animals, respectively. (C and D) Polarized light microscopy images with sirius red
staining showing type I collagen (red/yellow) and type-III collagen (green) in the EMG-cell free and EMG-ATDPC groups, respectively. Scale
bars ¼ 50 mm. (E) Collagen percentage—expressed as collagen volume fraction (CVF [%], left y-axis)—for total collagen, type I collagen (Col I),
and type III collagen (Col III); as well as the ratio between type I and III collagens (Col I/III ratio, right y-axis), for both the EMG-cell free and
EMG-ATDPC groups. Results are displayed as mean  SEM. *p ¼ 0.016, †p ¼ 0.002, ‡p ¼ 0.042, §p ¼ 0.032. Abbreviations as in Figure 1.
J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 1 , N O . 5 , 2 0 1 6 Perea-Gil et al.
A U G U S T 2 0 1 6 : 3 6 0 – 7 2 Novel Cell-Enriched Engineered Myocardial Graft
369
Perea-Gil et al. J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 1 , N O . 5 , 2 0 1 6
Novel Cell-Enriched Engineered Myocardial Graft A U G U S T 2 0 1 6 : 3 6 0 – 7 2
370availability, and generated in large quantities; and
second, some studies demonstrated feasible and
viable administration in clinical practice of decellu-
larized non-glutaraldehyde ﬁxed xenograft with no
associated side effects, immunological response, or
rejection (27), overcoming ﬁxation of porcine heart
valves before implantation in humans to reduce
immunogenicity and strengthen the tissue, but which
in turn would impede cell repopulation and in some
cases has led to calciﬁcation (28). Hence, clinical
translation of this xenograft should not be hampered
by regulatory issues.
On the other hand, the contribution of pATDPCs to
infarct repair is likely even more important, and may
be the key to understand post-MI recovery. The GFPþ
pATDPCs that migrated to the infarct core were pos-
itive for the endothelial markers SMA, IsoB4, and
CD31. Thus, cell delivery within the EMG contributed
to new blood vessel synthesis, as was previously re-
ported (14). This explains the higher vascular density
observed in EMG-ATDPC animals—which increases
the supplies of nutrients, oxygen, and endogenous
stem cells to the hypoxic area, probably preventing
infarct expansion due to EMG-ATDPC implantation
effect.
Most likely, paracrine effects would be the most
plausible mechanism by which pATDPCs exerted their
beneﬁcial effects, which has been broadly described
as one of the putative mechanisms for implanted cells
to regenerate the scarred area (29,30). Once placed on
top of the infarcted myocardium, the pATDPCs can
also exert autocrine and paracrine effects. They
secrete growth factors—such as vascular endothelial,
ﬁbroblast, hepatocyte and insulin growth factors, and
transforming growth factor-b—which increase the
vasculogenic, antiapoptotic/cardioprotective, and
proliferative activities, as well as the recruitment of
endogenous stem cells (31,32). It is also reported
pATDPCs secrete interleukin-6, -7, -8, and -11, which
act as phagocyte chemoattractants to eliminate cell
debris and encourage cellular turnover and regener-
ation (31). Such actions are consistent with the
reduced infarct size and enhanced vascular density
observed after EMG-ATDPC treatment, as well as the
higher cell proliferation displayed in the EMG-ATDPC
group. Moreover, collagen content reduction may be
correlated with the secretion of metalloproteinases
by pATDPCs, which inhibits collagen synthesis, as it
has been described for mesenchymal stem cells (33).
However, there is no clear explanation for the in-
crease in type III collagen. One possibility is that
synthesis of type III collagen increases when
pATDPCs are under mechanical stress or inside a
3-dimensional scaffold (34). The mechanical stimuliin the myocardium and the scaffold environment
could have up-regulated pATDPCs type III collagen
production, compensating for its degradation.
Along with the altered collagen content, we
observed a decrease in the ratio of type I to type III
collagen, indicating a reduction of collagen I deposi-
tion. Type III collagen is typically present during
wound healing, and organizes to form an elastic
ﬁbrillar network, providing a framework to ensure
correct alignment of type I collagen ﬁbers and main-
tenance of normal heart shape and myocardium
stiffness. On the other hand, type I collagen exhibits
high stiffness, thus permitting chamber remodeling
(35,36). Overall, the observed histopathological
changes—including neovascularization, infarct area
regeneration, and attenuation of ﬁbrosis—globally
enhanced cardiac function in terms of better LVEF,
which is the most clinically relevant parameter for
assessing heart function. Our results reﬂect an w11%
improvement in LVEF after MI in EMG-ATDPC group,
which is higher than the 3% to 4% enhancement ob-
tained with percutaneous coronary intervention (37),
the 4% registered with bone marrow cell therapies
(38), or the improvements obtained with other scaf-
folds in the swine MI model (13,39,40).
The reported feasibility and functional potential of
catheter delivery of a decellularized myocardial
scaffold in vivo (26) encouraged previous studies to
use such scaffolds in pre-clinical models, although
earlier studies showed little or modest beneﬁts.
Initial studies in the rat MI model produced contro-
versial results regarding LVEF. Although Singelyn
et al. (41) did not observe LVEF changes following
decellularized myocardial scaffold administration,
Dai et al. (42) reported a 4.3% increase in LVEF with
scaffold treatment compared with controls. Neither
study described higher neovascularization or altered
ﬁnal infarct size after scaffold treatment, nor
examined collagen content modiﬁcations (41,42).
Another study in rats investigated the addition of
mesenchymal progenitor cells into a decellularized
myocardial–ﬁbrin composite scaffold, and reported
increased angiogenesis, but did not assess LVEF,
infarct size, or collagen variations (43). Finally, a prior
work conducted in swine reported that administra-
tion of cell-free decellularized myocardial scaffold
did not signiﬁcantly affect LVEF when comparing
post-MI and ﬁnal LVEF values (13), in contrast to our
presently remarkable LVEF increase in EMG-ATDPC–
treated swine.
STUDY LIMITATIONS. One of the limitations in the
present study is the lack of a MI-only control group,
with no EMG-cell free or EMG-ATDPC implantation.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: MI remains a
top-ranked cause of death worldwide. Local delivery of
natural scaffolds repopulated with cardiac progenitor cells
(EMG-ATDPC) is a feasible approach with beneﬁcial impact in
cardiac function recovery. In our hands, the engraftment of a
cell-enriched engineered myocardial graft in the pre-clinical MI
model in swine resulted in better left ventricular ejection frac-
tion, higher vessel density and neovascularization, reduced
infarct size by 68%, and limited ﬁbrosis.
TRANSLATIONAL OUTLOOK: EMG-ATDPC implantation in
the infarcted myocardium improves cardiac recovery in the
porcine pre-clinical MI model. The design of a phase I to II clinical
trial in humans is mandatory to conﬁrm and validate safety and
efﬁcacy. Thus, the EMG-ATDPC is ready to start the translational
avenue toward ﬁrst-in-man clinical trials.
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371Although the data provided here by themselves
indicate a meaningful improvement in cardiac func-
tion and myocardial restoration in EMG-ATDPC–
treated animals, further studies including a MI-only
group may help in elucidating the role of the decel-
lularized myocardial scaffold and its beneﬁcial effects
over infarcted myocardium by itself.
Thus, the promising data reported here support
proceeding to clinical translation. Our group has
already started EMG-ATDPC production under good
manufacturing practice conditions and has initiated
the road to obtain approval by local regulators as ﬁrst
steps for a phase I clinical trial.
CONCLUSIONS
To summarize, we generated an EMG-ATDPC comp-
rising a decellularized myocardial scaffold that was
repopulated with pATDPCs. This EMG-ATDPC was
implanted in a swine MI model, and cardiac recovery
was assessed by CMR. The engrafted EMG-ATDPC
promoted revascularization of the damaged tissue,
reduced infarct size, attenuated ventricular remod-
eling and ﬁbrosis progression, and improved cardiac
function. This EMG-ATDPC is ready for clinical
translation.
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